

LARP2 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP56559

Product Information

Application	IHC-P, IHC-F, IF, ICC, E
Primary Accession	Q659C4
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	105322
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human LARP2
Epitope Specificity	11-100/914
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SUBCELLULAR LOCATION	Nuclear
SIMILARITY	Belongs to the LARP family. Contains 1 HTH La-type RNA-binding domain
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	This gene encodes a protein containing domains found in the La related protein of Drosophila melanogaster. La motif-containing proteins are thought to be RNA-binding proteins, where the La motif and adjacent amino acids fold into an RNA recognition motif. The La motif is also found in proteins unrelated to the La protein. Alternative splicing has been observed at this locus and multiple variants, encoding distinct isoforms, are described. Additional splice variation has been identified but the full-length nature of these transcripts has not been determined. [provided by RefSeq, Jun 2013]

Additional Information

Gene ID	55132
Other Names	La-related protein 1B, La ribonucleoprotein domain family member 1B, La ribonucleoprotein domain family member 2, La-related protein 2, LARP1B, LARP2
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,ICC=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name LARP1B

Synonyms LARP2

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.